OpenQ wins the 2009 Global Pharmaceutical CRM Growth Strategy Leadership of the Year presented by Frost & Sullivan
Charlottesville, VA, New York, NY and Paris, France (PRWEB) June 15, 2009 -- OpenQ, one of the industry leaders in KOL management solutions and MSL performance tools, announces that it has received the prestigious 2009 Global Pharmaceutical CRM Growth Strategy Leadership of the Year award, presented by Frost & Sullivan to the company that has demonstrated an exceptional growth strategy within the industry.
A recipient is chosen to receive the Frost & Sullivan Award for CRM Growth Strategy Leadership of the Year based on specific criteria. Through primary and secondary research methods, all companies' market revenues are tracked and those exhibiting significant growth are noted for their strategy implementation. Revenues are then compared year to year to monitor growth patterns. When a company consistently shows high growth rates, it is a candidate for the Frost & Sullivan Award Growth Strategy Leadership of the Year.
This accolade is given to the company that has bolstered their position in the market during the base year and whose strategy will have a profound and lasting impact on the market. The award criteria consist of the following:
- Ability to grow in a saturated or maturing market
- Implementing a unique sales strategy
- Technological innovation and leadership
- Discovering new venues for an established product
- Effective Internet strategy
- Strategic mergers, acquisitions, or joint ventures to penetrate new markets
- Reorganization structured around growth strategy
OpenQ provides the integrated insights and software solutions to meet the critical compliance, KOL, content and speaker needs facing Life Science companies, from development stage through maturity. Achieving another year of exponential growth, openQ serves its customers from various locations across North America, South America, Europe and Asia. OpenQ's growing list of customers includes 7 of the Top 10 pharmaceutical and 3 of the Top 5 medical device companies. For more information, visit http://www.openq.com
Read the full story at http://www.prweb.com/releases/2009/06/prweb2530554.htm.
Related biology technology :1
Copyright©2009 Vocus, Inc.
All rights reserved
. DNA2.0 Awarded US Patents for Breakthrough Gene Optimization Technology -- Company's Unique Algorithm Enables Expression Yields up to 50 Times Greater than Competing Approaches2
. Proplant Awarded Qatar Project3
. Plexus Awarded Development Contract With QIAGEN4
. Enerkem GreenField Alberta Biofuels Awarded Permit to Build Worlds First Commercial Municipal Waste-to-Biofuels Facility5
. ChanTest Awarded $4.8 Million Through the Ohio Third Frontier Research and Commercialization Program6
. CeNeRx BioPharma Awarded New Patent for its Innovative Compounds That Selectively Target Peripheral Cannabinoid Receptors7
. ArunA Biomedical Awarded Department of Defense Contract to Further Develop Environmental Biosensor for National Security8
. Peregrine Pharmaceuticals Awarded New U.S. Patent Further Strengthening Its Anti-Phospholipid Patent Portfolio9
. PCI Biotech-led Consortium Awarded EUR1.1 m Eurostars Grant for siRNA10
. Transgenomic Awarded Clinical Laboratory Certification in California11
. OLIGOMERIX Awarded NIH Grant to Develop Novel Biomarkers for Alzheimers Disease